Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

From Alzheimer's prevention to weight-loss dominance, Novo bets on innovation and share repurchases amid Medicare pressure.

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...

A new peer-reviewed study based on data from nearly 2M individuals highlights a wide range of clinical benefits and risks, ...

While the recent launches of GLP-1 drugs from Novo Nordisk and Eli Lilly have been nothing short of a staggering financial success, the rollouts have consistently been hamstrung by manufacturing ...

What does it do? Novo Nordisk-produced Ozempic, perhaps the best known of GLP-1 drugs, is a medication for the treatment of type 2 diabetes. How is it taken? It is injected at a rate of once a week.

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

As concerns around knockoffs of newer GLP-1 drugs like Ozempic and Wegovy take center stage, Novo Nordisk’s efforts to ward off competition against its aging diabetes blockbuster Victoza have ...

Coming off of Novo Nordisk's (NVO) sharp stock decline after ... which is their small molecule pill GLP-1, which could really open up the market. So I feel like Novo is kind of losing its pep ...

Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

Mounjaro's label notes, however, that the drug is contraindicated in patients with gastroparesis. Novo Nordisk sent pharmaphorum a statement noting that GLP-1 agonists have been used for years to ...